Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Withdrawn 1Recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2

Conditions

Carcinoma, Non-Small-Cell Lung 9Stomach Neoplasms 8Carcinoma, Hepatocellular 8Neoplasm Metastasis 7Triple Negative Breast Neoplasms 6Rectal Neoplasms 6Nasopharyngeal Carcinoma 6Melanoma 6Lymphoma, Extranodal NK-T-Cell 6Locally Advanced Rectal Cancer 6Colorectal Neoplasms 6Carcinoma, Renal Cell 6Squamous Cell Carcinoma of Head and Neck 5Sarcoma 4Pancreatic Neoplasms 4Uterine Cervical Neoplasms 3Small Cell Lung Carcinoma 3Cholangiocarcinoma 3Thyroid Neoplasms 2Nasopharyngeal Neoplasms 2Lymphoma, Large B-Cell, Diffuse 2Kidney Neoplasms 2Hemangiosarcoma 2Gastrointestinal Stromal Tumors 2Esophageal Squamous Cell Carcinoma 2Esophageal Neoplasms 2Adenocarcinoma Of Esophagus 2Uveal Melanoma 1Urinary Bladder Neoplasms 1Turcot syndrome 1

Interventions

Paclitaxel 6Doxorubicin 6Gemcitabine 4Bevacizumab 4pembrolizumab 3pazopanib 3durvalumab 3Sorafenib 3Docetaxel 3trebananib 2spartalizumab 2cemiplimab 2brostallicin 2Propranolol 2Nivolumab 2Magnetic Resonance Spectroscopy 2Ipilimumab 2Imatinib Mesylate 2Ifosfamide 2Carboplatin 23-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 2zanidatamab 1veliparib 1tucatinib 1trilaciclib 1tremelimumab 1trastuzumab duocarmazine 1temsirolimus 1talimogene laherparepvec 1talazoparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Hemangiosarcoma × spartalizumab × Clear all
NCT05961761 2023-07-27

PROPANE

Herlev and Gentofte Hospital

Phase 2 Recruiting
80 enrolled
Sarcoma

Hemangiosarcoma, Sarcoma, Histiocytoma, Malignant Fibrous

NCT04607200 2022-01-11

AGEN2034 & AGEN1884 in Patients With Recurrent, Inoperable Angiosarcoma

Agenus Inc.

Phase 2 Withdrawn
Sarcoma

Hemangiosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡